Law Offcie Logo

Topamax Birth Defect Lawyer, Topiramate Birth Defect Lawyer, Topamax Heart Defect Lawyer, Topamax Cleft Palate Lawyer, Topamax Cleft Lip Lawyer, and Antiepileptic Drug (APD) Birth Defect Lawyer (Topamax and Topiramate Birth Defect Lawsuits)

The FDA has recently announced that Topiramate (brand name Topamax) causes an increased risk of development of cleft lip and/or cleft palate (oral clefts) in infants born to women treated with Topamax (topiramate) during pregnancy. If you or a loved one have been taking Topamax during pregnancy and had a child with a birth defect, it is important to seek medical assistance.  If you have questions regarding a potential Topamax lawsuit for the death of a loved one or birth defect, please feel free to e-mail Texas Topamax Birth Defect Lawyer Jason Coomer with your name & contact information. or to submit an inquiry through this submission form.

Topamax Birth Defect Lawyer, Topiramate Birth Defect Lawyer, Topamax Heart Defect Lawyer, Topamax Cleft Palate Lawyer, Topamax Cleft Lip Lawyer, and Antiepileptic Drug (APD) Birth Defect Lawyer 
(Topamax and Topiramate Birth Defect Lawsuits)

Topiramate (brand name Topamax) is a anticonvulsant drug. It has been approved for the treatment of epilepsy and migraines, but has been aggressively marketed for many off-label uses including bipolar disorder, cluster headaches, eating disorders, obesity, fibromyalgia, depression, posttraumatic stress disorder (PTSD), alcoholism, sleep disorders, sleep-eating disorders, infantile spasms, autism, periventricular leukomalacia in preterm infants after an hypoxic-ischemic injury, essential tremor, bulimia nervosa, obsessive-compulsive disorder, smoking cessation, idiopathic intracranial hypertension, neuropathic pain, and cocaine dependence.  If you or a loved one have been taking Topamax during pregnancy and had a child with a birth defect, it is important to seek medical assistance.

The FDA recommends that "before starting topiramate, pregnant women and women of childbearing potential should discuss other treatment options with their health care professional. Women taking topiramate should tell their health care professional immediately if they are planning to or become pregnant. Patients taking topiramate should not stop taking it unless told to do so by their health care professional. Women who become pregnant while taking topiramate should talk to their health care professional about registering with the North American Antiepileptic Drug Pregnancy Registry, a group that collects information about outcomes in infants born to women treated with antiepileptic drugs during pregnancy."

Topamax Birth Defect Malformation Lawsuits and Cleft Lips or Palate Lawsuits (Topiramate Birth Defect Lawsuits)

The epilepsy and migraine drug Topamax has been associated with an increased risk of birth defects for children of mothers that were taking the drug during pregnancy. Research studies have found that there are higher than expected rates of babies born with cleft lips, cleft palates, genital defects and other birth malformations when Topamax is used by women during pregnancy.  Thus there is a growing amount of research that indicates that the use of the epilepsy and migraine drug, Topamax, either on its own or in combination with other epilepsy drugs, may increase the risk of birth defects when it is used during pregnancy.

In February 2011, U.S. Health Officials announced that Topamax increases the risk for birth defects in babies born to pregnant mothers taking the medication.  The Food and Drug Administration said new data shows the drug, sold generically and as Johnson & Johnson's Topamax, can cause cleft lips and cleft palate deformities. 

Drug Birth Defect Lawyer, Infant Malformation Lawyer, Cleft Palate Lawyer, Infant Heart Defect Lawyer, Texas Birth Defect Lawyer, Texas Cleft Lip Birth Defect Lawyer, Heart Defect Lawyer, Drug Pregnancy Lawyer, Infant Disability Lawyer, and Paxil Birth Defect Lawyer

Avoidable birth defects are one of the most devastating problems that can occur to a family and a new baby.  Parents who should be celebrating the birth of a new child, are often caught off guard when their child is born with severe disabilities and often do not realize that someone may be responsible for the birth defect including drug manufacturers that hid information about medications that can cause birth defects.  The family is typically busy taking care of the child with the serious health problems and often does not know that the birth defect was preventable.  When they discover the probable cause of the preventable birth defect they are often filled with anger and rage.  To find out that their child will have permanent health problems or that they lost their baby because a drug company hid research and did not provide an adequate warning of a product's safety can be extremely difficult.

Several medications, products, and drugs have been linked to birth defects.  Some of these medications were intentionally marketed by drug manufacturers that have hidden the real dangers of their product in order to sell more of their product and that value profits over healthy babies.  For these manufacturers, they may have short term profits, but over the long term they should suffer for the long term birth defects that they have caused.

Federal and Texas Birth Defect Lawyers, Drug Birth Defect Lawyer, Infant Heart Birth Defect Lawyer, Spina Bifida Lawyer, and Infant Malformation & Deformity Lawyer

Federal and Texas Birth Defect Lawsuits are some of the most complicated types of cases in the practice of law. As a Texas birth defect and birth injury lawyer that handles birth defect, infant death and stillborn baby claims, Jason S. Coomer works with other Birth Defect Lawyers throughout the United States including Boston Birth Defect Lawyers, Illinois Birth Defect Lawyers, Atlanta Birth Defect Lawyers, Virginia Birth Defect Lawyers, Dallas Birth Defect Lawyers, Houston Birth Defect Lawyers, and other Birth Defect Lawyers.  In working with other birth defect lawyers, we seek compensation from negligent drug companies, medical providers, and other companies that have severely injured or killed infants or mothers through selling and using dangerous products, medications, and drugs that they should have know were dangerous, but hid significant research in order to sell more product to make a profit.  If you have suffered the loss of your baby or your baby has been born with a significant birth defect, feel free to contact Texas Birth Defect Attorney, Jason S. Coomer.

Paroxetine, Seroxat, and Paxil Selective Serotonin Reuptake Inhibitor Antidepressants (SSRIs) PPHN Birth Defect Lawsuits

Paroxetine (trade names Seroxat, Paxil) is a selective serotonin reuptake inhibitor (SSRI) antidepressant that has been linked to birth defects including Persistent Pulmonary Hypertension (PPHN), heart, lung, abdominal and cranial defects.  Women that have taken Selective Serotonin Reuptake Inhibitor Antidepressants (SSRIs) after the 20th week of pregnancy have a 6-fold increased risk of having their child develop persistent pulmonary hypertension, a life-threatening lung disorderInfants with persistent pulmonary hypertension have abnormal blood flow through the heart and lungs and do not get enough oxygen to their bodies and may become very sick or die. 

The SSRIs antidepressants that have been linked to persistent pulmonary hypertension (PPHN) include Paxil by GlaxoSmithKline, Zoloft marketed by Pfizer; Prozac sold by Eli Lilly; Celexa and Lexapro by Forest Laboratories, Effexor marketed by Wyeth, Luvox by Solvay, and the generic makers of these drugs include Barr Pharmaceuticals, Ranbaxy Labs and Genpharm.

Infants born with PPHN often require mechanical assistance to breath and even worse about 10% to 20% of the infants do not survive even when they receive treatment. The PPHN babies that do survive often experience developmental delays, brain abnormalities and hearing loss, experts say.

Other birth defects that have been associated with SSRIs include Anencephaly, a neural tube defect where much of the brain does not develop; Craniosynostosis, an abnormality in which connections of the skull bones close prematurely; and Heart birth defects including septal defects and ventricular defects.

SSRIs have not only been associated to birth defects, but have been associated with increased risk of suicide.  For more information on suicide claims from antidepressants, please see our antidepressant suicide claim information page.

Depakote Birth Defect Lawsuit Information, Valproate Birth Defect Lawsuit Information, Spina Bifida Lawsuit Information & Defective Drug Birth Defect Lawsuit Information by Depakote Birth Defect Lawyer, Texas Birth Defect Lawyer, & Depakote Spina Bifida Lawyer Jason Coomer

Depakote also known as Valproate semisodium (INN), Depakote ER, Depakene, Depacon, Epival, Dépakine Chrono,Valance, and divalproex sodium (USAN) is a drug prescribed to treat seizures, migraine headaches, and some psychiatric disorders.  In the UK, Canada, and U.S., the drugs are used for the treatment of the manic episodes of bipolar disorder, major depressive disorder, prevention of both manic and depressive phases of bipolar disorder, epilepsy, chronic pain associated with neuropathy, and migraine headaches. Off-label use of the drug include treatment of mild depression, the depressive stage of bi-polar disorder, and chronic pain such as migraine headaches.

Depakote has been linked to major birth defects in children of women that were taking this drug.  According to a recent medical scientific study, women taking Depakote had four times the risk of delivering a child with major birth defects, compared to women taking other, similar drugs.  The range of birth defects associated with Depakote is broad, however the report specifically cited neural tube defects such as spina bifida. Neural tube defects are birth defects that affect the brain and spinal cord; spinal bifida is a defect affecting the spinal cord that causes paralysis of the legs.There is no known cure.

In addition to spina bifida, other birth defects caused by Depakote include cleft palate, cleft lip, heart defects, limb and digital deformities, facial dysmorphism, mental developmental delays, and (difficult) genitourinary maloformations.

If you believe that your child has suffered a birth defect or birth injury as a result of a defective drug, medication, or product, contact Depakote Birth Defect Lawyer Jason Coomer for a free review of your Depakote Birth Injury Lawsuit or Depakotel Birth Defect Lawsuit or use our online submission form.

Topamax and Topiramate FDA Approved Uses

Topamax (generic name: Topiramate) is an anticonvulsant drug also referred to as an antiepileptic drug (AED) that is produced by Ortho-McNeil Neurologics and Noramco, Inc., both divisions of Johnson & Johnson.  Topamax was first approved by the Food and Drug Administration in 1996 to treat epilepsy.  In 2010, Topamax is approved for use by itself or in combination with other meds to treat a variety of forms of epilepsy as well as to treat migraines. 

Off-Label Uses of Topamax and Topiramate

The Federal Food Drug and Cosmetic Act (”FDCA”), provides a systematic scheme for the approval of new drugs and new drug formulations intended to be marketed for use in interstate commerce. Under the FDCA, a new drug product cannot be marketed unless the FDA approves the product and determines that it is safe and effective for its intended use. When the FDA approves a drug, it approves the drug only for the particular use for which it was tested, but after the drug is approved for a particular use, the FDCA does not regulate how the drug may be prescribed. Thus, a drug that has been tested and approved for one use only can also be prescribed by a physician for another use, known as “off-label.”

Though physicians may prescribe drugs for off-label usage, the FDA prohibits drug manufacturers from marketing or promoting a drug for a use that the FDA has not approved. A manufacturer illegally “misbrands” a drug if the drug’s labeling includes information about its unapproved uses. A drug is deemed misbranded unless its labeling bears adequate directions for use. The courts have agreed with the FDA that the FDCA requires information not only on how a product is to be used (e.g. dosage and administration), but also on all the intended uses of the product. Oral statements and materials presented at industry-support scientific and educational activities may provide evidence of a product’s intended use. If these statements or materials promote a use that is inconsistent with the product’s approved labeling, the product is misbranded under the FDCA for failure to bear labeling with adequate directions for all intended uses.

Topamax is also being marketed for several off-label uses.  Some of the off-label uses of Topamax include for treatment of bipolar disorder, cluster headaches, eating disorders, obesity, fibromyalgia, depression, posttraumatic stress disorder (PTSD), alcoholism, sleep disorders, sleep-eating disorders, infantile spasms, autism, periventricular leukomalacia in preterm infants after an hypoxic-ischemic injury, essential tremor, bulimia nervosa, obsessive-compulsive disorder, smoking cessation, idiopathic intracranial hypertension, neuropathic pain, and cocaine dependence.

FDA Requires Warnings about Risk of Suicidal Thoughts and Behavior for Antiepileptic Drugs AEDs

In December 2008, the U.S. Food and Drug Administration announced it will require the manufacturers of antiepileptic drugs to add to these products' prescribing information, or labeling, a warning that their use increases risk of suicidal thoughts and behaviors (suicidality). The action includes all antiepileptic drugs including those used to treat psychiatric disorders, migraine headaches and other conditions, as well as epilepsy.

The FDA is also requiring the manufacturers to submit for each of these products a Risk Evaluation and Mitigation Strategy, including a Medication Guide for patients. Medication Guides are manufacturer-developed handouts that are given to patients, their families and caregivers when a medicine is dispensed. The guides will contain FDA-approved information about the risks of suicidal thoughts and behaviors associated with the class of antiepileptic medications.

"Patients being treated with antiepileptic drugs for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior," said Russell Katz, M.D., director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. " Patients who are currently taking an antiepileptic medicine should not make any treatment changes without talking to their health care professional."

The FDA today also disseminated information to the public about the risks associated with antiepileptic medications by issuing a public health advisory and an information alert to health care professionals. Health care professionals should notify patients, their families, and caregivers of the potential for an increase in the risk of suicidal thoughts or behaviors so that patients may be closely observed.

The FDA's actions are based on the agency's review of 199 clinical trials of 11 antiepileptic drugs which showed that patients receiving antiepileptic drugs had almost twice the risk of suicidal behavior or thoughts (0.43 percent) compared to patients receiving a placebo (0.24 percent). This difference was about one additional case of suicidal thoughts or behaviors for every 500 patients treated with antiepileptic drugs instead of placebo.

Four of the patients who were randomized to receive one of the antiepileptic drugs committed suicide, whereas none of the patients in the placebo group did. Results were insufficient for any conclusion to be drawn about the drugs' effects on completed suicides. The biological reasons for the increase in the risk for suicidal thoughts and behavior observed in patients being treated with antiepileptic drugs are unknown.

The FDA alerted health care professionals in January 2008 that clinical trials of drugs to treat epilepsy showed increased risk of suicidal thoughts and actions. In July 2008, the FDA held a public meeting to discuss the data with a committee of independent advisors. At that meeting the committee agreed with the FDA's findings that there is an increased risk of suicidality with the analyzed antiepileptic drugs, and that appropriate warnings should extend to the whole class of medications. The panel also considered whether the drugs should be labeled with a boxed warning, the FDA's strongest warning. The advisers recommended against a boxed warning and instead recommended that a warning of a different type be added to the labeling and that a Medication Guide be developed.

Acting under the authorities of the Food and Drug Administration Amendments Act of 2007 (FDAAA), the FDA is requiring manufacturers of antiepileptic drugs to submit to the agency new labeling within 30 days, or provide a reason why they do not believe such labeling changes are necessary. In cases of non-compliance, FDAAA provides strict timelines for resolving the issue and allows the agency to initiate an enforcement action if necessary.

The following antiepileptic drugs are required to add warnings about the risk of suicidality:

  • Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, Tegretol XR

  • Clonazepam (marketed as Klonopin)

  • Clorazepate (marketed as Tranxene)

  • Divalproex sodium (marketed as Depakote, Depakote ER)

  • Ethosuximide (marketed as Zarontin)

  • Ethotoin (marketed as Peganone)

  • Felbamate (marketed as Felbatol)

  • Gabapentin (marketed as Neurontin)

  • Lamotrigine (marketed as Lamictal)

  • Lacosamide (marketed as Vimpat)

  • Levetiracetam (marketed as Keppra)

  • Mephenytoin (marketed as Mesantoin)

  • Methosuximide (marketed as Celontin)

  • Oxcarbazepine (marketed as Trileptal)

  • Phenytoin (marketed as Dilantin)

  • Pregabalin (marketed as Lyrica)

  • Primidone (marketed as Mysoline)

  • Rufinamide (marketed as Banzel)

  • Tiagabine (marketed as Gabitril)

  • Topiramate (marketed as Topamax)

  • Trimethadione (marketed as Tridione)

  • Valproic Acid (marketed as Depakene, Stavzor Extended Release Tablets)

  • Zonisamide (marketed as Zonegran)

Antiepileptic Drug (AEDs), Anticonvulsant Drugs, and Topamax FDA Warnings and Safety Alerts (Topiramate Suicide Lawsuits)

On May 5, 2009, the FDA mandated a new warning for Topamax and all anticonvulsant drugs.  The antiepileptic drug (AED) class label changes mandated that Topamax and all anticonvulsant drugs update product labeling to include a warning about an increased risk of suicidal thoughts or actions.  Further, these manufacturers were directed to develop a Medication Guide to help patients understand the risk of suicidal thoughts or actions caused by the antiepileptic drugs. These changes affected all approved AEDs including Topamax except those indicated only for short-term use.

The FDA approved advice to be given to healthcare professionals is that "epilepsy and other illnesses for which antiepileptic drugs are prescribed are associated with an increased risk of suicidal thoughts and behavior. If suicidal thoughts or behavior emerge during treatment with AEDs, the prescriber should consider whether these symptoms may be related to the illness being treated. All patients who currently are taking or starting on any antiepileptic drug for any indication should be monitored for notable changes in behavior that could indicate the emergence or worsening of suicidal thoughts or behavior or depression."

Since the FDA issued safety alerts for the antiepileptic drugs on December 16, 2008 and January 31, 2008, FDA has been working with the manufacturers of drugs in this class to better understand the suicidality risk.  As described in the January 31, 2008, Information for Health Care Professionals Sheet on AEDS, eleven antiepileptic drugs were included in FDA’s original pooled analysis of placebo-controlled clinical studies in which these drugs were used to treat epilepsy as well as psychiatric disorders and other conditions.  The increased risk of suicidal thoughts or behavior was generally consistent among the eleven drugs, with varying mechanisms of action and across a range of indications. This observation suggests that the risk applies to all antiepileptic drugs used for any indication.

Topamax Birth Defect Lawyer, Topamax Cleft Palate Lawyer, Topamax Cleft Lip Lawyer, Topamax Hear Defect Lawyer, Topiramate Cleft Palate Lawyer, and Topiramate Birth Defect Lawyer

Texas Birth Defect Attorney Jason Coomer commonly works with other lawyers throughout Texas and the United States including Texas Topamax Birth Defect Lawyers, Houston Topiramate Birth Defect Lawyers, Boston Topamax Birth Defect Lawyers, San Antonio Birth Defect Lawyers, Dallas Off-label Topamax Infant Heart Problem Lawyers, and other Austin Dangerous Drug Infant Birth Defect Lawyers.  By sharing information and working together, his law firm and other firms throughout Texas and the United States are able to provide better representation for there clients.  

Texas Topamax Birth Defect Lawyer Jason Coomer works on catastrophic injury and death cases including defective drug mediation lawsuits. If you or a loved one were given Topamax or another Antiepileptic Drug (AED) during pregnancy and have had a child with a birth defect, please feel free to e-mail any questions you might have to TopamaxBirthDefectLawyer@texaslawyers.com.

Feel Free to Contact Us with any Questions

* Name (Required):
* Email (Required):
Phone Number:
* Your Message (Required):
Anti-spam Question:
*Using only numbers, what is 2 plus 2?

Law Offices of Jason S. Coomer, PLLC
406 Sterzing, Second Floor
Austin, TX 78704
Toll Free: (512) 474-1477
Phone: (866) 474-1477
Email: info@TexasLawyers.com

Follow Us on Social Media:

Click on a button below to share this page: